Citi Analysts Affirm Buy Rating on Gilead Sciences (GILD) Stock

On June 2, Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target. The analyst’s bullish stance follows the company presenting data from the ASCENT-04 trial at the American Society of Clinical Oncology (ASCO). The data showed significant progress in the development of Trodelvy as a novel treatment for triple-negative breast cancer (TNBC).

Citi Analysts Affirm Buy Rating and $125 Price Target on Gilead Sciences

A scientist in a laboratory holding a test tube filled with a glowing blue solution, representing the company’s nano-biopharmaceutical research and development.

Clinical trial data showed that when Trodelvy was combined with Keytruda, it significantly reduced the risk of disease progression or death in 35% of patients with PD-L1-positive metastatic TNBC. The combination treatment demonstrated a higher overall response rate of 60% compared to Keytruda and the chemotherapy group.

In addition, the combination improved median progression-free survival by 3.4 months to 11.2 months, which is better than 7.8 months for alternative treatment. Following the positive ASCENT-03 trial, Gilead Science plans to file for full approval, with a decision from the Food and Drug Administration expected in 2026.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. Its candidate drugs seek to improve the care of patients with life-threatening diseases worldwide.

While we acknowledge the potential of Gilead Sciences, Inc. (NASDAQ:GILD) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None.